Theseus Pharmaceuticals
314 Main Street
Cambridge
MA
02142
United States
Tel: 857-400-9491
Website: https://theseusrx.com/
Email: info@theseusrx.com
About Theseus Pharmaceuticals
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Public: THRX
42 articles about Theseus Pharmaceuticals
-
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
11/27/2023
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC.
-
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
11/7/2023
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14 at 9:45 a.m. ET.
-
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
8/10/2023
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the second quarter ended June 30, 2023.
-
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
7/13/2023
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced that it is discontinuing enrollment in the ongoing phase 1/2 study and terminating development of THE-630 in patients with gastrointestinal stromal tumors (GIST).
-
Theseus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
5/31/2023
Theseus Pharmaceuticals, Inc. announced that the company will participate in a live Fireside Chat at the Jefferies Healthcare Conference on June 8th at 10:30am ET.
-
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
5/25/2023
Theseus Pharmaceuticals, Inc. announced initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced gastrointestinal stromal tumors.
-
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
5/11/2023
Theseus Pharmaceuticals, Inc. today announced business highlights and reported financial results for the first quarter ended March 31, 2023.
-
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
4/26/2023
Theseus Pharmaceuticals, Inc. today announced that initial dose escalation data from the ongoing phase 1/2 study of THE-630 in advanced gastrointestinal stromal tumors (GIST) were accepted for online publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago, Illinois.
-
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
4/11/2023
Theseus Pharmaceuticals, Inc. today announced that the company will participate virtually in the following upcoming investor conferences.
-
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
3/28/2023
Theseus Pharmaceuticals, Inc. today announced that the company will participate in the Cantor Future of Oncology Virtual Symposium, taking place April 3-5, 2023.
-
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
3/9/2023
Theseus Pharmaceuticals, Inc. today announced business highlights and reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
2/7/2023
Theseus Pharmaceuticals, Inc. today announced that the Company will participate virtually in the SVB Securities Global Biopharma Conference, taking place February 14-16, 2023.
-
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
1/5/2023
Theseus Pharmaceuticals, Inc. announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor targeting BCR-ABL for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
-
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
10/19/2022
Theseus Pharmaceuticals, Inc. today announced the appointment of Steven Stein , M.D. to its Board of Directors.
-
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer
10/3/2022
Theseus Pharmaceuticals, Inc. today announced that it has nominated THE-349 as the development candidate for its epidermal growth factor receptor (EGFR) inhibitor program in non-small cell lung cancer (NSCLC).
-
Theseus Pharmaceuticals to Participate at Upcoming September 2022 Investor Conferences
9/6/2022
Theseus Pharmaceuticals, Inc. announced that the company will participate in-person at the following upcoming investor conferences.
-
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results
8/11/2022
Theseus Pharmaceuticals, Inc. today announced business and pipeline highlights and reported financial results for the second quarter ended June 30, 2022.
-
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
8/3/2022
Theseus Pharmaceuticals, Inc. today announced that it will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference, taking place August 9-10, 2022.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences - May 19, 2022
5/19/2022
Theseus Pharmaceuticals, Inc. announced that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022.